Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial | ||||||||||
By: Nasdaq / GlobeNewswire - 14 Aug 2019 | Back to overview list |
|||||||||
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it intends to provide its allogeneic cell therapy product candidate remestemcel-L for evaluation under an investigator-initiated Investigational New Drug (IND) submission as a potential treatment in children with steroid-refractory chronic graft-versus-host disease (GVHD). The lead investigator will be Dr Joanne Kurtzberg, Jerome Harris Distinguished Professor of Pediatrics and Professor of Pathology, and Director, Pediatric Blood and Marrow Transplant Program at Duke University Medical Center. In both acute and chronic forms of GVHD, the donated bone marrow stem cells view the recipient’s body as foreign, and attack the body causing significant morbidity and mortality. Acute GVHD usually manifests within 100 days following a transplant while chronic GVHD generally manifests later (>100 days), and the two may occur separately or within the same patient. The incidence of chronic GVHD is increasing and occurs in 30-70% of recipients of both related and unrelated bone marrow transplants.1,2 There are no therapies approved by the United States Food and Drug Administration (FDA) in the 50% of children with chronic GVHD who fail steroids. Mesenchymal stem cells have been used successfully in patients with steroid-refractory chronic GVHD and have been reported to result in durable responses in up to 75% of patients.3-5 Dr Kurtzberg said: “Given my experience with achieving successful outcomes with remestemcel-L in children with steroid-refractory acute GVHD, I look forward to evaluating the treatment’s potential as salvage therapy in chronic GVHD, where there remains a significant unmet need.” Earlier this year, Mesoblast initiated filing of a rolling submission for a Biologics License Application (BLA) to the FDA for the use of remestemcel-L in children with steroid-refractory acute GVHD. This BLA submission is based on a successful Phase 3 trial in 55 children with steroid-refractory acute GVHD and supporting results from an Expanded Access Program (EAP) in 241 children. Dr Kurtzberg was the Principal Investigator in both trials. About Mesoblast 1. Arai et al. Biol Blood Marrow Transplant. 2015; 21(2): 266–274. Forward-Looking Statements For further information, please contact:
|
||||||||||
|
||||||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |